CN110974847A - Method for treating lower limb ischemic diseases by using stem cells - Google Patents
Method for treating lower limb ischemic diseases by using stem cells Download PDFInfo
- Publication number
- CN110974847A CN110974847A CN201911352949.7A CN201911352949A CN110974847A CN 110974847 A CN110974847 A CN 110974847A CN 201911352949 A CN201911352949 A CN 201911352949A CN 110974847 A CN110974847 A CN 110974847A
- Authority
- CN
- China
- Prior art keywords
- mesenchymal stem
- stem cells
- phosphatidylserine
- sodium chloride
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 84
- 210000003141 lower extremity Anatomy 0.000 title claims abstract description 62
- 210000000130 stem cell Anatomy 0.000 title abstract description 23
- 201000002818 limb ischemia Diseases 0.000 title description 20
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 198
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims abstract description 173
- 239000000203 mixture Substances 0.000 claims abstract description 154
- 239000011780 sodium chloride Substances 0.000 claims abstract description 100
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 83
- 210000004027 cell Anatomy 0.000 claims abstract description 72
- 238000002659 cell therapy Methods 0.000 claims abstract description 66
- 210000003954 umbilical cord Anatomy 0.000 claims abstract description 44
- 239000011159 matrix material Substances 0.000 claims abstract description 23
- 230000001954 sterilising effect Effects 0.000 claims abstract description 19
- 208000023589 ischemic disease Diseases 0.000 claims abstract description 18
- 238000004806 packaging method and process Methods 0.000 claims abstract description 4
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 132
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 132
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 126
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 63
- 239000008215 water for injection Substances 0.000 claims description 52
- 238000002360 preparation method Methods 0.000 claims description 46
- UEAVLBXLOZNDHT-UHFFFAOYSA-K calcium;sodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxymethyl)amino]acetate Chemical compound [Na+].[Ca+2].OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEAVLBXLOZNDHT-UHFFFAOYSA-K 0.000 claims description 43
- 210000002826 placenta Anatomy 0.000 claims description 38
- 239000003814 drug Substances 0.000 claims description 34
- 238000011282 treatment Methods 0.000 claims description 34
- DJOCBZGOHLHHEO-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;calcium;sodium Chemical compound [Na].[Ca].OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O DJOCBZGOHLHHEO-UHFFFAOYSA-N 0.000 claims description 17
- 238000012258 culturing Methods 0.000 claims description 14
- 230000003169 placental effect Effects 0.000 claims description 11
- 229940071643 prefilled syringe Drugs 0.000 claims description 11
- 239000000243 solution Substances 0.000 claims description 10
- 238000005520 cutting process Methods 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims description 8
- 210000004369 blood Anatomy 0.000 claims description 7
- 239000008280 blood Substances 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 6
- -1 polypropylene Polymers 0.000 claims description 6
- QHPJDERMGHUORS-UHFFFAOYSA-N C=C.[Ca].[Na] Chemical group C=C.[Ca].[Na] QHPJDERMGHUORS-UHFFFAOYSA-N 0.000 claims description 5
- 238000009472 formulation Methods 0.000 claims description 5
- 239000001963 growth medium Substances 0.000 claims description 5
- 239000007853 buffer solution Substances 0.000 claims description 4
- 238000000227 grinding Methods 0.000 claims description 4
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 3
- 108010019160 Pancreatin Proteins 0.000 claims description 3
- 239000004743 Polypropylene Substances 0.000 claims description 3
- 239000000872 buffer Substances 0.000 claims description 3
- 229910002091 carbon monoxide Inorganic materials 0.000 claims description 3
- 210000001728 clone cell Anatomy 0.000 claims description 3
- 229910052802 copper Inorganic materials 0.000 claims description 3
- 239000010949 copper Substances 0.000 claims description 3
- 102000038379 digestive enzymes Human genes 0.000 claims description 3
- 108091007734 digestive enzymes Proteins 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 239000002609 medium Substances 0.000 claims description 3
- 210000005087 mononuclear cell Anatomy 0.000 claims description 3
- 229940055695 pancreatin Drugs 0.000 claims description 3
- 229920000642 polymer Polymers 0.000 claims description 3
- 229920001155 polypropylene Polymers 0.000 claims description 3
- 238000004659 sterilization and disinfection Methods 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 2
- 229940071106 ethylenediaminetetraacetate Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000011084 recovery Methods 0.000 abstract description 14
- 230000000694 effects Effects 0.000 abstract description 12
- 230000004083 survival effect Effects 0.000 abstract description 12
- 230000035899 viability Effects 0.000 abstract description 7
- 230000004071 biological effect Effects 0.000 abstract description 2
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 238000002156 mixing Methods 0.000 description 35
- 239000012467 final product Substances 0.000 description 32
- 229940079593 drug Drugs 0.000 description 26
- 210000001519 tissue Anatomy 0.000 description 26
- 210000004556 brain Anatomy 0.000 description 22
- 239000007788 liquid Substances 0.000 description 19
- 241000700159 Rattus Species 0.000 description 18
- 206010012601 diabetes mellitus Diseases 0.000 description 18
- 238000005303 weighing Methods 0.000 description 18
- 239000007864 aqueous solution Substances 0.000 description 17
- 239000006285 cell suspension Substances 0.000 description 17
- 206010022562 Intermittent claudication Diseases 0.000 description 16
- 230000003833 cell viability Effects 0.000 description 16
- 238000001816 cooling Methods 0.000 description 16
- 239000004615 ingredient Substances 0.000 description 16
- 208000021156 intermittent vascular claudication Diseases 0.000 description 16
- 230000003902 lesion Effects 0.000 description 14
- 230000000250 revascularization Effects 0.000 description 14
- 210000004204 blood vessel Anatomy 0.000 description 11
- 238000001356 surgical procedure Methods 0.000 description 11
- 208000024891 symptom Diseases 0.000 description 11
- 230000001225 therapeutic effect Effects 0.000 description 11
- 206010003178 Arterial thrombosis Diseases 0.000 description 10
- 230000015654 memory Effects 0.000 description 9
- 210000003205 muscle Anatomy 0.000 description 9
- 239000008055 phosphate buffer solution Substances 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 239000006143 cell culture medium Substances 0.000 description 8
- 238000005138 cryopreservation Methods 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 210000004379 membrane Anatomy 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 108010028554 LDL Cholesterol Proteins 0.000 description 7
- 238000002266 amputation Methods 0.000 description 7
- 210000001185 bone marrow Anatomy 0.000 description 7
- 210000000170 cell membrane Anatomy 0.000 description 7
- 230000000302 ischemic effect Effects 0.000 description 7
- 230000007774 longterm Effects 0.000 description 7
- 208000032064 Chronic Limb-Threatening Ischemia Diseases 0.000 description 6
- 206010034576 Peripheral ischaemia Diseases 0.000 description 6
- 230000001154 acute effect Effects 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 230000004069 differentiation Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 210000003414 extremity Anatomy 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000010257 thawing Methods 0.000 description 6
- 206010017711 Gangrene Diseases 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 5
- 208000007536 Thrombosis Diseases 0.000 description 5
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 5
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 5
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 5
- 210000004958 brain cell Anatomy 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 5
- 210000005036 nerve Anatomy 0.000 description 5
- 230000036407 pain Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 208000025865 Ulcer Diseases 0.000 description 4
- 230000001464 adherent effect Effects 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 210000001367 artery Anatomy 0.000 description 4
- 230000007211 cardiovascular event Effects 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 210000003090 iliac artery Anatomy 0.000 description 4
- 208000028867 ischemia Diseases 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 210000003137 popliteal artery Anatomy 0.000 description 4
- 208000037803 restenosis Diseases 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 230000002537 thrombolytic effect Effects 0.000 description 4
- 231100000397 ulcer Toxicity 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 102000002265 Human Growth Hormone Human genes 0.000 description 3
- 108010000521 Human Growth Hormone Proteins 0.000 description 3
- 239000000854 Human Growth Hormone Substances 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000011038 discontinuous diafiltration by volume reduction Methods 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 210000001339 epidermal cell Anatomy 0.000 description 3
- 210000001105 femoral artery Anatomy 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 230000036651 mood Effects 0.000 description 3
- 239000002858 neurotransmitter agent Substances 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000000246 remedial effect Effects 0.000 description 3
- 230000000284 resting effect Effects 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000001502 supplementing effect Effects 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 206010058178 Aortic occlusion Diseases 0.000 description 2
- 200000000007 Arterial disease Diseases 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 229930192334 Auxin Natural products 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 208000026350 Inborn Genetic disease Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 2
- 230000036626 alertness Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 239000002363 auxin Substances 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000019771 cognition Effects 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 238000009207 exercise therapy Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 208000016361 genetic disease Diseases 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 231100000862 numbness Toxicity 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 2
- 230000007480 spreading Effects 0.000 description 2
- 238000003892 spreading Methods 0.000 description 2
- 229960001052 streptozocin Drugs 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- ZAVXXBAIPSQJGS-UHFFFAOYSA-B tetracalcium;tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O.[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O.[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O ZAVXXBAIPSQJGS-UHFFFAOYSA-B 0.000 description 2
- 210000003556 vascular endothelial cell Anatomy 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- GWHCXVQVJPWHRF-KTKRTIGZSA-N (15Z)-tetracosenoic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCCCC(O)=O GWHCXVQVJPWHRF-KTKRTIGZSA-N 0.000 description 1
- 102100022464 5'-nucleotidase Human genes 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- 108050000824 Angiotensin II receptor Proteins 0.000 description 1
- 102000008873 Angiotensin II receptor Human genes 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 208000031104 Arterial Occlusive disease Diseases 0.000 description 1
- 206010060965 Arterial stenosis Diseases 0.000 description 1
- 208000000575 Arteriosclerosis Obliterans Diseases 0.000 description 1
- 244000286893 Aspalathus contaminatus Species 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 208000033386 Buerger disease Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102100035882 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 244000050510 Cunninghamia lanceolata Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 208000008960 Diabetic foot Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 206010014513 Embolism arterial Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 208000003790 Foot Ulcer Diseases 0.000 description 1
- 201000000628 Gas Gangrene Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 208000033892 Hyperhomocysteinemia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 102100022338 Integrin alpha-M Human genes 0.000 description 1
- 108010005714 Interferon beta-1b Proteins 0.000 description 1
- 208000035901 Ischaemic ulcer Diseases 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- XJXROGWVRIJYMO-SJDLZYGOSA-N Nervonic acid Natural products O=C(O)[C@@H](/C=C/CCCCCCCC)CCCCCCCCCCCC XJXROGWVRIJYMO-SJDLZYGOSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 206010038563 Reocclusion Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 206010040860 Skin haemorrhages Diseases 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 206010043540 Thromboangiitis obliterans Diseases 0.000 description 1
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 210000001691 amnion Anatomy 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 206010002906 aortic stenosis Diseases 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 208000021328 arterial occlusion Diseases 0.000 description 1
- 206010003230 arteritis Diseases 0.000 description 1
- 208000028922 artery disease Diseases 0.000 description 1
- 239000002473 artificial blood Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229940021459 betaseron Drugs 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940040591 biotech drug Drugs 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000007213 cerebrovascular event Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- GWHCXVQVJPWHRF-UHFFFAOYSA-N cis-tetracosenoic acid Natural products CCCCCCCCC=CCCCCCCCCCCCCCC(O)=O GWHCXVQVJPWHRF-UHFFFAOYSA-N 0.000 description 1
- 229940069078 citric acid / sodium citrate Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000011082 depyrogenation Methods 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000002327 glycerophospholipids Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 230000003225 hyperhomocysteinemia Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 210000003111 iliac vein Anatomy 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 235000001705 insufficient nutrition Nutrition 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000013152 interventional procedure Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000000608 laser ablation Methods 0.000 description 1
- 238000013147 laser angioplasty Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007787 long-term memory Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 238000010197 meta-analysis Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 208000015001 muscle soreness Diseases 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000009251 neurologic dysfunction Effects 0.000 description 1
- 208000015015 neurological dysfunction Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 238000002670 nicotine replacement therapy Methods 0.000 description 1
- 229940063137 norditropin Drugs 0.000 description 1
- 229940063149 nutropin Drugs 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 238000002355 open surgical procedure Methods 0.000 description 1
- 210000004409 osteocyte Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 229960001539 poliomyelitis vaccine Drugs 0.000 description 1
- 201000006292 polyarteritis nodosa Diseases 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000011946 reduction process Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000002254 renal artery Anatomy 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 230000005586 smoking cessation Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- VIDRYROWYFWGSY-UHFFFAOYSA-N sotalol hydrochloride Chemical compound Cl.CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 VIDRYROWYFWGSY-UHFFFAOYSA-N 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000002438 stress hormone Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000009120 supportive therapy Methods 0.000 description 1
- 210000000331 sympathetic ganglia Anatomy 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 238000013151 thrombectomy Methods 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 210000004026 tunica intima Anatomy 0.000 description 1
- 210000004231 tunica media Anatomy 0.000 description 1
- 231100000216 vascular lesion Toxicity 0.000 description 1
- 206010055031 vascular neoplasm Diseases 0.000 description 1
- 230000007497 verbal memory Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000001755 vocal effect Effects 0.000 description 1
- 238000004260 weight control Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention relates to a method for treating ischemic diseases of lower limbs by stem cells. The cell therapy composition for treating ischemic diseases of lower limbs comprises: umbilical cord mesenchymal stem cells, sodium chloride, and water. The cell therapy composition is prepared as follows: dissolving sodium chloride in water, optionally sterilizing the solution to obtain matrix; suspending the prepared mesenchymal stem cells in the matrix, and packaging. The invention also relates to a method for preparing said cell therapy compositions, and to their medical use. The method of the present invention exhibits excellent technical effects as described in the specification, for example, the composition obtained by the present invention exhibits excellent cell recovery performance during cell recovery, and the viability of cells undergoing recovery process and the survival stability of cells after recovery are significantly higher than those of the prior art solutions. In addition, the compositions of the present invention exhibit more beneficial biological activity.
Description
Technical Field
The invention belongs to the field of medical biotechnology, and relates to a method for treating and/or preventing acute and/or chronic lower limb ischemic diseases, a pharmaceutical composition used in the method, and application of the composition in treating the lower limb ischemic diseases. In particular, to methods and compositions for treating ischemic conditions of the lower extremities using stem cells.
Background
Ischemic disease of lower limbs is a common disease, seriously affects the life quality of patients, and even endangers life. The ischemic disease of the lower limb refers to a disease with ischemic manifestations such as Intermittent Claudication (IC), ulcer, gangrene and the like of the lower limb caused by arterial stenosis or occlusion and insufficient blood flow perfusion of the lower limb due to various reasons. The most common causes of ischemic diseases in the lower extremities are arteriosclerosis obliterans (LEAO) in the lower extremities due to arteriosclerosis, and other non-arteriosclerotic causes, such as arterial embolism in the lower extremities, thromboangiitis obliterans, aortic stenosis, fibrodysplasia in the arterial muscles of the lower extremities, aortic arteritis, polyarteritis nodosa, persistent sciatic artery, popliteal artery compression syndrome, cystic degeneration of the popliteal artery adventitia, popliteal aneurysm, primary vascular tumor, fibrosis in the iliac artery, and thrombosis in the arteries due to various hypercoagulative states.
Ischemic diseases of the lower limbs can be clinically divided into stages I-IV: phase I, mild phase: the main symptoms in this stage are cold and cool feeling, slight numbness, and fatigue after activity; phase II, intermittent claudication phase: at the moment, the patients suffered from limb fatigue, weakness and muscle soreness after walking can completely relieve symptoms after rest, and the walking distance and the rest time are generally fixed; in stage III, the patient feels restful and also feels numbness and pain when resting; the pain worsens at night; stage IV, necrotic tissue, ischemic ulcers or extensive necrosis of the extremities. Often, phases I and II are treated with medications, including analgesics, anticoagulants, and antiplatelet agents. Often, stage III and IV are performed with interventional procedures including balloons, stents, atherectomy, etc., or electrical spinal cord stimulation, sympathetic ganglion blocking, or nerve amputation. The ischemic disease of lower limbs of diabetes refers to the disease of chronic ischemia and anoxia of limbs caused by arteriosclerosis and stenosis of lower limbs during the occurrence, development and treatment of diabetes, the curative effect of conventional medicines is very little, the long-term curative effect of some patients through interventional therapy or vascular bypass surgery is not ideal, especially the arterial outflow tract of lower limbs is blocked and compensatory collateral is formed, and the blood vessels are difficult to be re-introduced by any means. With the development of stem cell basic research and clinical application, a new treatment means is provided for patients with diabetes lower limb ischemia, after stem cells are transplanted into lower limb muscles of patients with diabetes lower limb ischemia, vascular endothelial cells, epidermal cells and the like are induced and generated under an ischemia and hypoxia environment to form new capillaries, regenerate epidermis, gradually differentiate and form new capillaries, so that the purposes of promoting the regeneration of the blood vessels and improving and recovering the blood flow of affected limbs of patients with diabetes lower limb ischemia are achieved; however, the risk of collecting peripheral blood or bone marrow stem cells is high, and the requirements on the age, physical conditions and psychological acceptance degree of patients are high; the number and differentiation capacity of autologous stem cells of diabetic patients are reduced, and endothelial progenitor cells in peripheral blood of the diabetic patients are reduced, and the proliferation potential, adhesion and angiogenisis capacity of the endothelial progenitor cells are reduced. Compared with bone marrow and autologous peripheral blood stem cells, the umbilical cord has rich resources, more primitive mesenchymal stem cells and stronger amplification capacity, can obtain enough stem cells after induced differentiation, has stronger differentiation capacity towards blood vessels, bones, muscles and nerves, has more effective stem cell potential, and has simple cell collection, easy acquisition and weak immunogenicity.
Mesenchymal Stem Cells (MSCs) are a heterogeneous group of cells derived from a matrix, and can be obtained from most tissues of the human body. A large number of experimental researches show that the mesenchymal stem cells have epidermal cell differentiation potential and can promote the healing of the wounded skin. The bone marrow derived mesenchymal stem cells are not suitable for batch preparation because of the hidden danger of virus pollution, and the cell number, the amplification and differentiation capacity of the bone marrow derived mesenchymal stem cells are obviously reduced along with the age increase of donors. The mesenchymal stem cells derived from human umbilical cord, placenta or amnion successfully avoid a plurality of limitations of embryonic stem cell source deficiency, variant rejection, moral ethics and the like, and become a good substitute of the bone marrow-derived mesenchymal stem cells; they have self-renewal, tissue repair, immunoregulatory ability, and can differentiate into mesodermal lineage, such as adipocytes, osteocytes, chondrocytes, etc., and also into other mesodermal lineage cells, such as epidermal cells, vascular endothelial cells; and the cells are easy to expand in vitro, and the differentiation capacity and the proliferation capacity are kept stable after expansion, so that the method is suitable for large-scale preparation.
There are known reports on the use of mesenchymal stem cells for the treatment of ischemic diseases of the lower limbs. However, when the method is applied to clinic, a plurality of technical problems such as insufficient biological effect need to be faced. Therefore, it would be highly desirable to provide a method and composition comprising mesenchymal stem cells and useful for treating ischemic diseases of lower limbs.
Disclosure of Invention
It is another object of the present invention to provide a method and composition for treating ischemic diseases of lower limbs using stem cells, and particularly, the cell therapeutic composition can be used for treating ischemic diseases of lower limbs. It has been surprisingly found that the compositions of the present invention have excellent properties.
The invention is realized by the following scheme.
In a first aspect of the present invention, there is provided a cell therapy composition for treating ischemic disease of lower limbs, the composition comprising: mesenchymal stem cells (may be abbreviated as MSCs, the source of which may be, for example, umbilical cord or placenta), phosphatidylserine, sodium chloride, and water.
The cell therapy composition according to the present invention, wherein the mass volume percentage of the phosphatidylserine is 0.1% to 0.3%.
The cell therapy composition according to the present invention, wherein the mass volume percentage of the phosphatidylserine is 0.15% to 0.25%.
The cytotherapeutic composition according to the present invention, wherein the mass volume percentage of the phosphatidylserine is 0.2%.
The cell therapy composition according to the present invention, wherein the mesenchymal stem cells have a density of 2 x107one/mL to 5X 107one/mL.
The cell therapy composition according to the present invention, wherein the mesenchymal stem cells have a density of 3 x107one/mL.
The cell therapy composition according to the present invention, wherein the mass volume percentage of the sodium chloride is 0.8% to 1.0%.
The cell therapy composition according to the present invention, wherein the mass volume percentage of the sodium chloride is 0.9%.
The cell therapy composition according to the present invention further comprises magnesium chloride.
The cell therapy composition according to the present invention, wherein the mass volume percentage of the magnesium chloride is 0.05% to 0.1%.
The cytotherapeutic composition according to the present invention, wherein the mass volume percentage of the magnesium chloride is 0.08%.
The cell therapy composition according to the present invention further comprises calcium sodium ethylenediaminetetraacetate.
The cell therapy composition provided by the invention is characterized in that the mass volume percentage of the ethylenediaminetetraacetic acid calcium sodium salt is 0.02-0.05%.
The cell therapy composition according to the invention, wherein the mass volume percentage of the calcium sodium ethylene diamine tetraacetate is 0.03%.
The cell therapy composition according to the present invention, wherein the mass volume percentage of phosphatidylserine is 0.1%, and the density of mesenchymal stem cells is 3 x107The mass volume percentage of sodium chloride per mL is 0.9%.
The cell therapy composition according to the present invention, wherein the mass volume percentage of phosphatidylserine is 0.2%%, and the density of mesenchymal stem cells is 5 x107The mass volume percentage of sodium chloride per mL is 0.9%.
The cell therapy composition according to the present invention, wherein the mass volume percentage of phosphatidylserine is 0.3%, and the density of mesenchymal stem cells is 5 x107The mass volume percentage of sodium chloride per mL is 0.9%.
The cell therapy composition according to the invention is characterized in that:
(1) which comprises the following steps: placenta mesenchymal stem cell 4X 107one/mL, phosphatidylserine 0.2%, sodium chloride 0.9%, magnesium chloride 0.08%, calcium sodium ethylene diamine tetraacetate 0.03% and water for injection;or,
(2) which comprises the following steps: placenta mesenchymal stem cell 2X 107one/mL, phosphatidylserine 0.3%, sodium chloride 0.8%, magnesium chloride 0.1%, calcium sodium ethylene diamine tetraacetate 0.02% and water for injection; or,
(3) which comprises the following steps: placenta mesenchymal stem cell 5 × 107one/mL, phosphatidylserine 0.1%, sodium chloride 1.0%, magnesium chloride 0.05%, calcium sodium ethylene diamine tetraacetate 0.05% and water for injection; or,
(4) which comprises the following steps: placenta mesenchymal stem cell 3X 107one/mL, phosphatidylserine 0.2%, sodium chloride 0.9%, magnesium chloride 0.08%, calcium sodium ethylene diamine tetraacetate 0.04% and water for injection; or,
(5) which comprises the following steps: umbilical cord mesenchymal stem cells 4 x107one/mL, phosphatidylserine 0.2%, sodium chloride 0.9%, magnesium chloride 0.08%, calcium sodium ethylene diamine tetraacetate 0.03% and water for injection; or,
(6) which comprises the following steps: umbilical cord mesenchymal stem cell 2 x107one/mL, phosphatidylserine 0.3%, sodium chloride 0.8%, magnesium chloride 0.1%, calcium sodium ethylene diamine tetraacetate 0.02% and water for injection; or,
(7) which comprises the following steps: umbilical cord mesenchymal stem cell 5 x107one/mL, phosphatidylserine 0.1%, sodium chloride 1.0%, magnesium chloride 0.05%, calcium sodium ethylene diamine tetraacetate 0.05% and water for injection; or,
(8) which comprises the following steps: umbilical cord mesenchymal stem cells 3X 107one/mL, phosphatidylserine 0.2%, sodium chloride 0.9%, magnesium chloride 0.08%, calcium sodium ethylene diamine tetraacetate 0.04% and water for injection.
In the cell therapy composition of the present invention, the survival rate is greatly reduced due to insufficient nutrition if the density of the stem cells is too high, the survival rate is not maintained due to too low density of the stem cells, and the amount of the preparation required is increased due to too low density of the stem cells. The invention proves that the density of the stem cells is 2 multiplied by 10 through experiments7one/mL to 5X 107The survival rate of stem cells is highest when the cells are cultured per mL.
The compositions of the present invention are aqueous suspensions comprising sodium chloride at a concentration substantially equivalent to physiological saline. The normal saline is sodium chloride solution with osmotic pressure equal to that of animal or human plasma, which is commonly used in physiological experiments or clinic. Therefore, the mesenchymal stem cells in the cell therapy composition of the present invention are basically dispersed in physiological saline, i.e., sodium chloride solution with a mass volume percentage of 0.9%, and the osmotic pressure of the composition is consistent with that of human tissues, and the mesenchymal stem cells are not damaged by using the physiological saline as a solvent.
Phosphatidylserine is an important membrane phospholipid present in bacterial, yeast, plant, mammalian cells. Phosphatidylserine is also called compound nervonic acid. The English name Phosphatidylserine, PS for short, is extracted from natural soybean oil residues. Are active substances of cell membranes, in particular in brain cells. The functional components mainly improve nerve cell function, regulate the conduction of nerve pulse and enhance brain memory function, and the lipophilic components can quickly enter the brain through a blood brain barrier after being absorbed due to strong lipophilicity, thereby playing the roles of relieving blood vessel smooth muscle cells and increasing blood supply of the brain. Phosphatidylserine is also called serine phospholipid, diacylglycerolphosphateserine, a ubiquitous phospholipid, usually located in the inner layer of cell membrane, and the phosphoglycerides in phospholipid compounds, one of the cell membrane components, are related to a series of membrane functions. Especially in the nervous system of human body, it is one of the important components of the cell membrane of brain, and plays an important role in regulating various functions of brain (especially the memory and emotional stability of brain), such as it can affect the fluidity and permeability of cell membrane, and activate the metabolism and synthesis of various enzymes. For example, there are phosphatidylcholine (19% in human red blood cell membranes), sphingomyelin (8% in human red blood cell membranes), phosphatidylethanolamine (16% in human red blood cell membranes), and phosphatidylserine (10% in human red blood cell membranes). And only the latter has a net negative charge on the cell membrane, contributing to membrane asymmetry. It also activates prothrombin on the damaged surface. And can be converted with phosphatidylcholine and phosphatidylethanolamine in vivo. Phosphatidylserine actually constitutes a generic term for a class of compounds due to the differences between R1 and R2. First extracted and characterized by Jordi Folch in 1942. PS consists of three parts: the hydrophilic glycerol backbone is the head and the lipophilic groups of the two longer hydrocarbon chains are the tails. The head consists of three groups: the serine residue is combined with the phosphate residue and then is connected with the hydroxyl of the C-3 glycerol; the other two hydroxyl groups of glycerol form a tail after being esterified with fatty acids respectively. The fatty acid at the C-2 position of glycerol generally has a longer carbon chain and more unsaturated bonds than the fatty acid at the C-1 position. Phosphatidylserine (PS) refers to a group of compounds, not a single component, because the acetyl residues of products extracted from raw materials of different origin vary greatly. PS is amphiphilic, i.e., it is both hydrophilic and lipophilic. Its structure determines its unique properties, the negatively charged head being hydrophilic (or water soluble) and the tail consisting of fatty acids being lipophilic (or fat soluble). Phosphatidylserine (PS) can be synthesized by human body using serine, which can affect the transmission of chemical information in brain, and help brain cells to store and read data, and is an important nutrient element for maintaining normal memory, response and healthy mood of brain. Phosphatidylserine is known as an emerging "intelligent nutrient" following choline and "brain gold" DHA. Experts believe that this natural substance helps cell walls to remain flexible and can enhance the efficiency of neurotransmitters that transmit brain signals, help the brain to operate efficiently, and stimulate the brain's activation state. Specifically, phosphatidylserine has the following functions. (1) Improving brain function, concentrating attention, and improving memory. The united states of europe has shown a large number of meta-analyses of phosphatidylserine (meta-analysis refers to systematic quantitative or qualitative integration of multiple independent findings on a problem), which mainly aims to reflect the previous findings in a more objective manner. In 9 double-blind, placebo-controlled, 1224 patients participating in clinical trials were analyzed and the results showed significant improvement in cognitive and memory parameters following phosphatidylserine supplementation. Needless to say, supplementation with phosphatidylserine can improve long-term memory, long-term cognition, and the ability to speak freely and logically. With age, phosphatidylserine and other important brain chemicals are gradually diminished, resulting in diminished memory and cognition. Supplementing phosphatidylserine can increase the number of brain spurs, the fluidity of brain cell membranes and promote the metabolism of glucose in brain cells, thereby activating brain cells, promoting concentration of attention and improving alertness and memory. Phosphatidylserine supplements are widely used in italy, scandinavia peninsula and other countries in europe to treat age-induced cognitive impairment and senile memory loss. (2) The learning ability is improved. Phosphatidylserine has been tested specifically for its effect in relieving stress, using a double-blind, placebo-controlled trial with 300 mg phosphatidylserine given to healthy college students every day for 30 consecutive days. College students must complete a difficult mathematical test in a given time and record their response to stress. As a result, the students using phosphatidylserine were found to have better response, confidence and performance than the control group, and to have better performance in the examination. A study of students in the third and higher grades also found that students taking fortified phosphatidylserine had significantly improved verbal and non-verbal memory after 40 days. (3) Relieving stress, promoting recovery of brain fatigue, and balancing mood. Multiple studies show that phosphatidylserine can obviously reduce the level of excessive stress hormone in the body of a person with work stress, relieve pressure and relieve brain fatigue; phosphatidylserine also acts on the level of mood-affecting neurotransmitters in the brain, and can promote concentration, improve alertness and memory, and help alleviate undesirable mood (e.g., depression, etc.). (4) Helping repair brain damage. Phosphatidylserine is one of the main components of brain nerves, can nourish and activate the activity of various enzymes in the brain, can delay the reduction process of neurotransmitter, and is helpful for repairing and updating damaged cells of the brain and removing harmful substances. It can restore memory of the elderly to a level 14 years ago, and research shows that after taking phosphatidylserine for 12 weeks, 66 years old have memory of 52 years old. In addition, phosphatidylserine and DHA can mutually promote absorption and play a role in protecting nerve 2A cells. The abundant phosphatidylserine can increase the fluidity of cell membranes and promote the development of intelligence. The phosphatidylserine and DHA can protect central nervous system and promote fetal intelligence development. Studies have shown that phosphatidylserine can enhance human intelligence primarily because it can rapidly cross the blood-brain barrier and enter the brain. The composition has the effects of relieving cerebral capillary smooth muscle cells and increasing blood supply to the brain. Therefore, in recent years, many products for stroke use PS as a raw material.
The molecular formula of the calcium sodium ethylene diamine tetracetate used in the invention is C10H12N2O8CaNa2.2H2O, and the calcium sodium ethylene diamine tetracetate is white crystal particles or white to offwhite powder, and the pH value of a 1% aqueous solution of the calcium sodium ethylene diamine tetracetate is 6.0-7.0. Calcium sodium ethylene diamine tetracetate is odorless, slightly salty, slightly hygroscopic, stable in air, easily soluble in water and hardly soluble in ethanol, is usually used as a chelating agent, a preservative and an antioxidant, has the effect of stabilizing the quality of a product by combining free metals, and is usually used for eliminating the inhibition of enzyme catalytic reaction caused by trace heavy metals.
The cell therapy composition according to the present invention, wherein the mesenchymal stem cell is a mesenchymal stem cell of primary to tenth generations.
The cell therapeutic composition according to the present invention, wherein the mesenchymal stem cell may be derived from various known routes, for example, it may be derived from bone marrow, umbilical cord or placenta.
The cell therapy composition according to the present invention, wherein the method for obtaining mesenchymal stem cells is well known, for example, the method described in CN102586184A (2012100446386) for obtaining mesenchymal stem cells from placenta.
The cell therapy composition according to the present invention, wherein the method for obtaining mesenchymal stem cells is well known, for example, the method for obtaining mesenchymal stem cells from umbilical cord as described in CN102660497A (2012101599162).
The cell therapeutic composition according to the present invention, wherein said mesenchymal stem cells are obtained by a method comprising the steps of (placenta-derived):
(a) washing the placental lobules sufficiently with PBS buffer to remove residual blood from the placenta;
(b) cutting placenta lobule into pieces, adding PBS buffer solution containing tissue digestive enzyme, and incubating and digesting at 37 deg.C;
(c) filtering the tissue mass with a copper mesh, grinding if necessary to facilitate filtration;
(d) centrifuging the collected filtrate, separating mononuclear cells, suspending the obtained cells in MSC medium, and then adding 5% CO at 37 deg.C2Culturing in an incubator;
(e) after the cells are scattered to form clones, selecting each clone cell, respectively culturing by using an MSC culture medium, and after the cells are fused, digesting and passaging by using pancreatin to obtain the placenta mesenchymal stem cell. Passaging was performed if necessary and/or frozen in liquid nitrogen for future use.
The cell therapy composition according to the present invention, wherein the mesenchymal stem cell is obtained by a method comprising the steps of (umbilical cord-derived):
(1) umbilical cord tissue adherence treatment: taking cell culture plates, spreading the tissue blocks in the plates, and keeping the number of the tissue blocks in each plate at 5-20, so that the tissue blocks are air-dried for 2-50 minutes until the tissue is attached to the plates;
(2) umbilical cord tissue culture: slowly adding a mesenchymal stem cell culture medium along the edge of the plate until the tissue is submerged; placing the plate in CO2Culturing in a 5% culture box at 37 deg.C, taking out the plate from the culture box when culturing for 3-7 days, and supplementing with appropriate amount of mesenchymal stem cell culture medium; removing the culture medium in the plate on days 9-11, adding a proper amount of fresh mesenchymal stem cell culture medium, and continuously culturing; removing all umbilical cord tissue pieces and continuing culturing on days 11-13; then, the liquid is changed once every 1 to 3 days;
(3) cell passage: when the fusion rate of adherent cells in the dish reaches 50-70%, the adherent cells are separated from the bottom of the dish by using trypLEexpress; centrifuging, removing supernatant, adding mesenchymal stem cell culture medium to resuspend cells, inoculating to a T25 cell culture bottle, and performing passage and amplification culture; and then, changing the liquid every 1 to 3 days until the fusion rate reaches 70 to 90 percent, thus obtaining the umbilical cord mesenchymal stem cells. Passaging was performed if necessary and/or frozen in liquid nitrogen for future use. Detecting one or more of the following items of the obtained mesenchymal stem cells when necessary: cell viability, cell contamination, genetic disease, HLA-ABC/DR match.
The cell therapy composition according to the present invention is prepared according to a method comprising the steps of:
dissolving phosphatidylserine and sodium chloride (and optionally magnesium chloride and/or optionally calcium sodium ethylenediaminetetraacetate) in water, optionally sterilizing the solution to obtain matrix of the preparation; [ Note that, the substrate obtained at the concentration of phosphatidylserine used in the present invention is a clear solution, i.e., the extent to which phosphatidylserine is dissolved ]
Suspending the prepared mesenchymal stem cells in the matrix, and packaging.
The cell therapy composition according to the present invention, wherein the matrix of the preparation is sterilized by a means selected from the group consisting of: filtering, sterilizing, and sterilizing under hot pressure. In the embodiment of the present invention, the sterilization is autoclaving, unless otherwise specified.
The cell therapy composition according to the present invention is prepared under aseptic conditions.
The cell therapy composition according to the present invention, during the preparation thereof, the temperature of the matrix before mixing with the mesenchymal stem cells is less than 25 ℃.
The cell therapy composition according to the present invention is prepared by mixing the matrix with the mesenchymal stem cells at a temperature of less than 25 ℃.
The preparation method of the cell therapy composition of the mesenchymal stem cells provided by the invention is simple and mild, and the activity of the stem cells can not be damaged, so that the survival rate of the stem cells in the mesenchymal stem cell preparation is improved.
The cell therapy composition according to the present invention, wherein the dispensing is dispensing the formulated cell therapy composition into pre-filled syringes, particularly into disposable pre-filled syringes.
In the cell therapy composition according to the present invention, the syringe of the prefilled syringe is made of a polymer (e.g., polypropylene) and the piston is made of rubber, and in the embodiment of the present invention, as not particularly illustrated, the syringe of the prefilled syringe is made of a polymer (e.g., polypropylene) and the piston is made of rubber.
Prefilled syringes were first introduced during world war ii in order to meet the field sterile medical needs of field hospitals. The re-forced marketing of prefilled syringes was in the early 50 s of the last century when Becton Dickinson provided glass prefilled syringes for the polio vaccine program of Jonas Salks, Rooibos. Thereafter, prefilled syringes continue to be used, mostly in the field of insulin and human growth hormone administration. However, the real prevalence of pre-filled syringes has been in the past 5 years, almost becoming a product that must be provided by the injection supplier. While most of the innovative liquid drugs, if appropriate, will be marketed in prefilled syringes. Pre-filled syringes are especially appealing due to the advantages of the product itself, especially ease of use. The pharmaceutical market is changing, biotechnological therapies and the number of drug candidates that can be administered only by injection route is increasing, and they are involved in a very wide range of therapeutic fields, such as multiple sclerosis, infertility, osteoporosis, hepatitis, rheumatoid arthritis, cancer, anemia and hemophilia. Some biotech drugs require frequent administration by the patient himself, who benefits most deeply from the convenience of a prefilled syringe, since the prefilled syringe saves some handling steps and allows a faster and easier use. The need of the patient is a real motivation to advance the development of prefilled syringes. The metering of a drug from a vial into a syringe is a time consuming task and is prone to error by persons lacking adequate training. In addition, patients with certain diseases such as rheumatoid arthritis often have difficulty, if not even being able to hold a stable vial and measure out the correct dose. Pharmaceutical manufacturers have changed some drugs from lyophilized to liquid dosage forms to fill prefilled syringes, for example Berlex's therapeutic multiple sclerosis drug Betaseron, norkino's human auxin Norditropin, and gene tack's human auxin Nutropin have all changed from lyophilized to liquid dosage forms to fill prefilled syringes for sale. Syringe component manufacturers are speeding up to meet the ever increasing demand for ready-to-use components. The ready-to-use plunger from Stelmi, France and the Hypak SCF prefilled syringe from Becton Dickinson, make filling on-site without the need for cleaning, depyrogenation and sterilization operations. The ready-to-use element can be directly used after being cleaned, sterilized by ethylene oxide or gamma rays and verified. Another advantage of prefilled syringes is that the amount of product overfill can be significantly reduced. By using the prefilled syringe, 10%, 15%, and sometimes even 20% of the drug substance can be saved. Some manufacturers that change vials to prefilled syringes also reduce the bulk drug yield because the new dosage form no longer requires as much bulk drug. One study by Becton Dickinson showed that the dose in a prefilled syringe can be 23% higher than a vial because there is less drug loss during transfer from vial to syringe.
In a second aspect of the present invention, there is provided a method for preparing a cell therapeutic composition for treating ischemic diseases of lower limbs, comprising: mesenchymal stem cells (which may be derived from, for example, umbilical cord or placenta), phosphatidylserine, sodium chloride, and water.
The method according to the present invention, wherein the cell therapy composition further comprises magnesium chloride and/or sodium calcium ethylenediaminetetraacetate.
The method according to the invention comprises the following steps:
dissolving phosphatidylserine and sodium chloride (and optionally magnesium chloride and/or optionally calcium sodium ethylenediaminetetraacetate) in water, optionally sterilizing the solution to obtain matrix of the preparation;
suspending the prepared mesenchymal stem cells in the matrix, and packaging.
According to the method of the present invention, the mass volume percentage of the phosphatidylserine in the cell therapy composition is 0.1% to 0.3%.
According to the method of the present invention, the mass volume percentage of the phosphatidylserine in the cell therapy composition is 0.15% to 0.25%.
According to the method of the present invention, the mass volume percentage of the phosphatidylserine in the cytotherapeutic composition is 0.2%.
According to the method of the present invention, in the cell therapy composition, the density of the mesenchymal stem cells is 2 x107one/mL to 5X 107one/mL.
According to the method of the present invention, in the cell therapy composition, the density of the mesenchymal stem cells is 3 x107one/mL.
According to the method of the present invention, the mass volume percentage of the sodium chloride in the cell therapy composition is 0.8% to 1.0%.
According to the method of the present invention, the mass volume percentage of the sodium chloride in the cell therapy composition is 0.9%.
According to the method of the present invention, the cell therapy composition further comprises magnesium chloride.
According to the method of the present invention, the mass volume percentage of the magnesium chloride in the cell therapy composition is 0.05% to 0.1%.
According to the method of the present invention, the mass volume percentage of the magnesium chloride in the cytotherapeutic composition is 0.08%.
According to the method of the present invention, the cell therapy composition further comprises calcium sodium edetate.
According to the method, in the cell therapy composition, the mass volume percentage of the calcium sodium ethylene diamine tetraacetate is 0.02-0.05%.
According to the method, the mass volume percentage of the EDTA calcium sodium in the cell therapy composition is 0.03%.
According to the method of the invention, the cell therapy composition comprises 0.1% by mass of phosphatidylserine and 3 × 10% by mass of mesenchymal stem cells7The mass volume percentage of sodium chloride per mL is 0.9%.
According to the method of the invention, the cell therapyIn the therapeutic composition, the mass volume percentage of phosphatidylserine is 0.2%, and the density of mesenchymal stem cells is 5 × 107The mass volume percentage of sodium chloride per mL is 0.9%.
According to the method of the present invention, the cell therapy composition comprises phosphatidylserine in an amount of 0.3% by mass and mesenchymal stem cells in an amount of 5 × 107The mass volume percentage of sodium chloride per mL is 0.9%.
The method according to the invention is characterized in that it produces a cytotherapeutic composition,
(1) which comprises the following steps: placenta mesenchymal stem cell 4X 107one/mL, phosphatidylserine 0.2%, sodium chloride 0.9%, magnesium chloride 0.08%, calcium sodium ethylene diamine tetraacetate 0.03% and water for injection; or,
(2) which comprises the following steps: placenta mesenchymal stem cell 2X 107one/mL, phosphatidylserine 0.3%, sodium chloride 0.8%, magnesium chloride 0.1%, calcium sodium ethylene diamine tetraacetate 0.02% and water for injection; or,
(3) which comprises the following steps: placenta mesenchymal stem cell 5 × 107one/mL, phosphatidylserine 0.1%, sodium chloride 1.0%, magnesium chloride 0.05%, calcium sodium ethylene diamine tetraacetate 0.05% and water for injection; or,
(4) which comprises the following steps: placenta mesenchymal stem cell 3X 107one/mL, phosphatidylserine 0.2%, sodium chloride 0.9%, magnesium chloride 0.08%, calcium sodium ethylene diamine tetraacetate 0.04% and water for injection; or,
(5) which comprises the following steps: umbilical cord mesenchymal stem cells 4 x107one/mL, phosphatidylserine 0.2%, sodium chloride 0.9%, magnesium chloride 0.08%, calcium sodium ethylene diamine tetraacetate 0.03% and water for injection; or,
(6) which comprises the following steps: umbilical cord mesenchymal stem cell 2 x107one/mL, phosphatidylserine 0.3%, sodium chloride 0.8%, magnesium chloride 0.1%, calcium sodium ethylene diamine tetraacetate 0.02% and water for injection; or,
(7) which comprises the following steps: umbilical cord mesenchymal stem cell 5 x107one/mL, 0.1 percent of phosphatidylserine, 1.0 percent of sodium chloride,0.05% of magnesium chloride, 0.05% of calcium sodium ethylene diamine tetraacetate and water for injection; or,
(8) which comprises the following steps: umbilical cord mesenchymal stem cells 3X 107one/mL, phosphatidylserine 0.2%, sodium chloride 0.9%, magnesium chloride 0.08%, calcium sodium ethylene diamine tetraacetate 0.04% and water for injection.
According to the method of the present invention, in the cell therapy composition, the mesenchymal stem cell is a mesenchymal stem cell of primary to tenth generations.
In the cell therapy composition according to the method of the present invention, the mesenchymal stem cell may be derived from various known sources, for example, it may be derived from bone marrow, umbilical cord or placenta.
According to the method of the present invention, the method for obtaining mesenchymal stem cells in the cell therapy composition is well known, and for example, the method described in CN102586184A (2012100446386) is a method for obtaining mesenchymal stem cells from placenta.
According to the method of the present invention, the mesenchymal stem cells are obtained by a well-known method, for example, the method described in CN102660497A (2012101599162) from umbilical cord.
According to the method of the present invention, in the cell therapy composition, the mesenchymal stem cells are obtained by a method comprising the steps of (placenta-derived):
(a) washing the placental lobules sufficiently with PBS buffer to remove residual blood from the placenta;
(b) cutting placenta lobule into pieces, adding PBS buffer solution containing tissue digestive enzyme, and incubating and digesting at 37 deg.C;
(c) filtering the tissue mass with a copper mesh, grinding if necessary to facilitate filtration;
(d) centrifuging the collected filtrate, separating mononuclear cells, suspending the obtained cells in MSC medium, and then adding 5% CO at 37 deg.C2Culturing in an incubator;
(e) after the cells are scattered to form clones, selecting each clone cell, respectively culturing by using an MSC culture medium, and after the cells are fused, digesting and passaging by using pancreatin to obtain the placenta mesenchymal stem cell. Passaging was performed if necessary and/or frozen in liquid nitrogen for future use.
According to the method of the present invention, in the cell therapy composition, the mesenchymal stem cells are obtained by a method comprising the steps of (umbilical cord-derived):
(1) umbilical cord tissue adherence treatment: taking cell culture plates, spreading the tissue blocks in the plates, and keeping the number of the tissue blocks in each plate at 5-20, so that the tissue blocks are air-dried for 2-50 minutes until the tissue is attached to the plates;
(2) umbilical cord tissue culture: slowly adding a mesenchymal stem cell culture medium along the edge of the plate until the tissue is submerged; placing the plate in CO2Culturing in a 5% culture box at 37 deg.C, taking out the plate from the culture box when culturing for 3-7 days, and supplementing with appropriate amount of mesenchymal stem cell culture medium; removing the culture medium in the plate on days 9-11, adding a proper amount of fresh mesenchymal stem cell culture medium, and continuously culturing; removing all umbilical cord tissue pieces and continuing culturing on days 11-13; then, the liquid is changed once every 1 to 3 days;
(3) cell passage: when the fusion rate of adherent cells in the dish reaches 50-70%, the adherent cells are separated from the bottom of the dish by using trypLEexpress; centrifuging, removing supernatant, adding mesenchymal stem cell culture medium to resuspend cells, inoculating to a T25 cell culture bottle, and performing passage and amplification culture; and then, changing the liquid every 1 to 3 days until the fusion rate reaches 70 to 90 percent, thus obtaining the umbilical cord mesenchymal stem cells. Passaging was performed if necessary and/or frozen in liquid nitrogen for future use.
Detecting one or more of the following items of the obtained mesenchymal stem cells when necessary: cell viability, cell contamination, genetic disease, HLA-ABC/DR match.
According to the process of the present invention, the preparation thereof is carried out under aseptic conditions.
According to the method of the present invention, the temperature of the matrix is less than 25 ℃ before mixing with the mesenchymal stem cells during the preparation process.
According to the method of the present invention, the matrix is mixed with the mesenchymal stem cells at a temperature of less than 25 ℃ during the preparation process.
The preparation method of the cell therapy composition of the mesenchymal stem cells provided by the invention is simple and mild, and the activity of the stem cells can not be damaged, so that the survival rate of the stem cells in the mesenchymal stem cell preparation is improved.
According to any aspect of the present invention, wherein the cell therapy composition comprises magnesium chloride and/or optionally calcium sodium edetate in specified amounts, it has been surprisingly found that the combination of magnesium chloride and/or calcium sodium edetate provides a composition that exhibits superior cell recovery performance when the cells are thawed after cryopreservation, and that the viability of the cells undergoing the cryopreservation recovery process and the stability of the cells after recovery is significantly higher than other solutions without magnesium chloride and calcium sodium edetate. Furthermore, the present inventors have also surprisingly found that the addition of a prescribed amount of phosphatidylserine to the cell therapy composition of the present invention can significantly increase the capillary density after the use of a cell therapy agent.
The cell therapy composition of mesenchymal stem cells provided by the present invention is preferably an injectable composition, which is in an injection liquid state at normal temperature, the injection liquid being suitable for intramuscular administration (intramuscular injection) to a mammalian subject (preferably a human patient). For example, the cell therapeutic composition of mesenchymal stem cells provided by the present invention is also suitable for local administration, such as intramuscular injection, to a mammalian subject, preferably a human patient, at or near the lower limb ischemic disease differential. The cell therapy composition of the mesenchymal stem cells provided by the invention can increase the density of capillaries of lower limbs and treat or prevent ischemic diseases of lower limbs and related symptoms thereof when being applied to a mammalian subject (particularly a human patient).
The invention also relates to a method for the treatment and/or prevention of a condition selected from the above-mentioned diseases or conditions, in particular ischemic diseases of the lower extremities, comprising the steps of: a sufficient amount of the cell therapy composition of mesenchymal stem cells of the present invention is administered to a mammalian subject (preferably a human patient), e.g. by intramuscular administration, in particular in a lower limb muscle of a mammalian subject (preferably a human patient).
In the above-described steps of the preparation method of the present invention, although the specific steps described therein are distinguished in some detail or in language description from the steps described in the preparation examples of the detailed embodiments below, those skilled in the art can fully summarize the above-described method steps in light of the detailed disclosure throughout the present disclosure.
Any embodiment of any aspect of the invention may be combined with other embodiments, as long as they do not contradict. Furthermore, in any embodiment of any aspect of the invention, any feature may be applicable to that feature in other embodiments, so long as they do not contradict. The invention is further described below.
All documents cited herein are incorporated by reference in their entirety and to the extent such documents do not conform to the meaning of the present invention, the present invention shall control. Further, the various terms and phrases used herein have the ordinary meaning as is known to those skilled in the art, and even though such terms and phrases are intended to be described or explained in greater detail herein, reference is made to the term and phrase as being inconsistent with the known meaning and meaning as is accorded to such meaning throughout this disclosure.
There are documents (Chenjiexin, et al, lower limb ischemic disease standardization treatment dispute and consensus, China journal of Utility surgery 2017,37(12): 1349-.
1. The control of Risk factors, hypertension, diabetes, smoking, hyperlipidemia, hyperhomocysteinemia, obesity, chronic renal insufficiency, etc., are major Risk factors for LEAO.reasonable control of Risk factors helps slow progression of LEAO, prevents the occurrence of cardiovascular and cerebrovascular events.major Risk factor control measures and goals include (1) smoking cessation, including self-smoking cessation or cessation by nicotine replacement therapy, etc. (2) weight control, bringing Body Mass Index (BMI) to a range of 20-25. (3) lowering the level of low-density lipoprotein cholesterol (LDL-C). for patients at high Risk for cardiovascular events LDL-C <1.8mmol/L (70 mg/dL); patients at high Risk for cardiovascular events LDL-C <2.6mmol/L (100 g/dL); patients at high Risk for cardiovascular events LDL-C < 3.4mmol/L (130 mg/dL); patients with LDL-C <2.6mmol/L (100 g/dL); patients with LDL-C < 11 mmol/L > (3583 mg/dL); and optionally, using a cardiovascular pressure-lowering agent as a systemic angiotensin-lowering agent, preferably, or lowering angiotensin-receptor-binding, and reducing blood pressure in patients at Risk levels of the index of the relevant to patients.
2. The study on whether the platelet-free anticoagulant therapy is more effective in patients with acute or chronic arterial thrombosis, more severe arterial thrombosis, more than more severe arterial thrombosis, more than more severe arterial thrombosis, more than more severe arterial thrombosis, more than more severe arterial thrombosis, more than more severe arterial thrombosis, more than more severe arterial thrombosis, more than more severe arterial thrombosis, more than more severe arterial thrombosis, more than more recently, more than more recently.
3. Exercise treatment and tissue defect minimization management for patients with lower limb ischemic diseases. Exercise is an important component of treatment for LEAO patients. Regular exercise can relieve the symptoms of ischemia of lower limbs, improve the painless walking distance and the maximum walking distance, and improve the life quality and the life capacity. The recommended walking exercise method is 30-45 min for each walk, at least 3 times per week and at least 12 weeks. In addition, LEAO patients, especially those with diabetes, should be instructed to perform self-tests and healthy foot movements to avoid trauma and burns to help reduce the incidence of diabetic foot, lower limb ulcers and amputations. Once foot ulcer gangrene is found, high attention should be paid and medical treatment should be carried out in time.
4. Revascularization in IC patients. Whether an IC LEAO patient needs revascularization or not and which way to use for revascularization should be determined comprehensively in combination with the ischemic symptoms of the patient, the degree of influence of the symptoms on the quality of life and the functional status of the body, the risk factors of the patient merging, the risk-benefit ratio of the revascularization procedure to the patient, the subjective desire of the patient and the requirement of the patient on the quality of life. In IC patients, unlike the treatment of Critical Limb Ischemia (CLI), revascularization aims to alleviate symptoms while maximizing the rate of long-term patency after revascularization. There are currently some irregularities in the treatment of IC patients: (1) only the blood vessel reconstruction treatment is paid attention to, and the life guidance, the exercise and the basic drug treatment are ignored. (2) One treatment is based on the pathological changes, without considering the symptoms and the requirements on the quality of life of the patients. (3) Only the patency rate is considered, and the long-term patency rate after vascular reconstruction is ignored. Patients with the same lesions of bilateral SFA are often seen with reocclusion after revascularization on one side, with the result that symptoms are even more severe than on the non-pretreated side. The standardized process flow of IC patients can be referred to the 2017 ESC guideline, and it should be emphasized that: (1) patients with simple IC should be given exercise therapy (preferably supervised exercise therapy) and drug therapy for 3 months, and then whether revascularization is needed is determined according to the treatment effect. The timing and indications of treatment, lesions of different location and extent may be somewhat controversial: for the single iliac artery TASC A/B disease, whether treatment indication can be relaxed to intervene more actively or not is determined due to higher patency rate after treatment in a lesion cavity; IC patients with simple SFA lesions, especially long-segment lesions, can appropriately tighten the revascularization indication in consideration of the patency rate after reconstruction. (2) The IC patients with isolated below-knee artery lesion try to select exercise treatment and drug treatment. (3) Although intraluminal treatment of IC patients with lesions of the main iliac artery, under the current technical conditions, can have a good patency rate even in the case of TASC grade D lesions, if the patient is younger, the general situation is good, and the revascularization procedure is recommended to be the first choice in view of the long-term patency rate of the vessel. In addition, flat renal aortic occlusion and aortic occlusion affecting the renal arteries should be considered as much as possible for open surgical reconstruction in cases where the patient can tolerate it. (4) All lesions affecting the common femoral artery should be considered as hybrid surgery or open surgery. (5) The importance of exercise and medication should be fully appreciated for IC patients with simple SFA lesions. If the blood vessel reconstruction is needed, the patency rate after reconstruction should be fully considered: if the lesion is too long (>25cm) or restenosis following endoluminal treatment, if the patient is tolerant or the condition of the native vein is acceptable, open surgery is considered to be an option, while other patients are treated endoluminally. (6) For IC patients, the native vein is the first choice for the femoral popliteal artery bypass surgery, and when the conditions of the native vein are poor, the selection of the artificial blood vessel can be considered for the femoral popliteal artery bypass surgery. The femoral-subclavian artery bypass surgery is not suitable for patients with simple IC. (7) Drug-coated balloons have certain advantages for IC patients with SFA short segment lesions (<25cm) and in-stent restenosis.
5. Revascularization in CLI patients. CLI is the most severe manifestation of LEAO, with a very poor prognosis, with a high amputation rate and mortality. Therefore, CLI patients should be actively revascularized under conditional warranty with the goal of reestablishing effective lower limb blood flow to lower the plane of amputation, or to reduce resting pain, promote ulcer healing, strive to minimize tissue defects, preserve lower limb function as much as possible, and improve quality of life. The treatment process of severe lower limb ischemia can refer to the ESC guideline of 2017. Extensive diffuse chronic lesions of the lower limbs are more prone to open surgical procedures. Those with non-healing ulcers or gangrene in the limb often require reference to the Angiosome concept to reestablish as much as possible of the blood flow to the foot. Patients with simple resting pain may be considered to take a staged intervention. If a limb has gangrene with severe infection (such as gas gangrene or septicaemia), emergency amputation may be a necessary option. For persistent ischemic rest pain, CLI patients with a short expected survival time, rational analgesia and other supportive therapies may be the best treatment modalities, and amputation may also be considered if necessary.
6. Various revascularization modalities for LEAO patients. The modes of vascular reconstruction for LEAO patients mainly comprise intracavity treatment, open surgery treatment and compound surgery. Particularly, the most treatment modes currently available for the intracavity treatment include common balloon dilatation, balloon dilatation and stent, drug-coated balloon (DCB), drug-coated balloon and remedial stent, drug stent, intracavity volume reduction (rotary cutting, laser ablation, suction), intracavity volume reduction and drug-coated balloon and remedial stent, covered stent and the like. However, which mode is optimal is not yet determined, and the data of the corresponding clinical research is relatively limited. The drug-coated balloon is a widely accepted intracavity therapeutic apparatus at present, and can act on the tunica media in the blood vessel through drugs to achieve the purpose of inhibiting the hyperplasia of the tunica intima in the blood vessel. In the drug-coated balloon age, stents have become unnecessary and the concept of "free balloon catheter" has been keenly understood. However, it should be noted that the drug-coated balloon is not all-round, and has a certain limitation in the application of the drug-coated balloon for severe calcification lesions. Lumen retraction and dissection following drug-coated balloon therapy also continues to require the application of corresponding remedial stents. In addition, drug-coated balloons are also not always feasible, and although they can improve patency rates of 1 and 2 years after endoluminal treatment, they do not significantly improve the long-term patency rate of DCB as indicated by the DEBATE-ISR study. In the treatment of below-knee artery disease, the application of drug-coated balloons is more controversial: some studies suggest that drug-coated balloons can improve restenosis rate and reoccurrence rate 1 year after intraluminal treatment of below-knee arteriopathy; however, other studies have suggested that the advantages of DCB in reducing restenosis and re-intervention rates are not significant during the 12-month follow-up period, and may instead increase the rate of significant amputation. The authors concluded that this differentiation could also be associated with a DCB class difference in the absence of standard wound management protocols. In addition, volume reduction technology (including directional atherectomy, percutaneous mechanical thrombectomy, excimer laser angioplasty and the like) can be combined with the drug-coated balloon for application, so that the patency rate after revascularization is further improved, but clinical research data of larger samples are lacked at present.
7. Revascularization of acute lower limb ischemia. On one hand, the reason for inducing acute lower limb ischemia needs to be actively searched, and on the other hand, the blood vessel needs to be actively rebuilt on the basis of the administration of anticoagulation treatment. The reconstruction modes comprise catheter thrombolysis, intracavity thrombus suction, incision and thrombus removal, bypass surgery and the like. Catheter thrombolysis and intracavitary thrombus aspiration can be used in combination to reduce the dose of thrombolytic drugs and improve the patency rate. The PTA +/-stent can be used for assisting in treating residual vascular lesions after thrombolysis or thrombus removal. However, in the case of patients with severe ischemia, especially acute lower limb ischemia with neurological dysfunction, the blood circulation should be started as soon as possible, and the catheter thrombolysis alone is not suitable for such patients.
The cell therapy composition of the mesenchymal stem cells provided by the invention has excellent properties.
Detailed Description
The present invention will be further described by the following examples, however, the scope of the present invention is not limited to the following examples. It will be understood by those skilled in the art that various changes and modifications may be made to the invention without departing from the spirit and scope of the invention. The present invention has been described generally and/or specifically with respect to materials used in testing and testing methods. Although many materials and methods of operation are known in the art for the purpose of carrying out the invention, the invention is nevertheless described herein in as detail as possible. The following examples further illustrate the invention without limiting it. Hereinafter, the mesenchymal stem cell is a mesenchymal stem cell of the fifth generation, unless particularly stated. Herein, the concentration of the mesenchymal stem cell suspension obtained with reference to CN102586184A or CN102660497A is more than 10, as not otherwise specified9Per ml, so as to be used in the subsequent dilution process when the composition is formulated.Example 1 compositions of placental MSCs
Ingredient ratio (concentration) of the final product: mesenchymal stem cell, 4 × 107Per mL; phosphatidylserine, 0.2%; 0.9 percent of sodium chloride; water for injection and the rest.
The preparation method comprises the following steps: mesenchymal stem cells were obtained from placenta by the method described in examples 1 to 2 in reference to CN102586184A (2012100446386). Weighing phosphatidylserine and sodium chloride, adding a proper amount of water for injection to dissolve, carrying out autoclaving at 121 ℃ for 15 minutes, and cooling for later use; mixing the mesenchymal stem cell suspension with the aqueous solution of phosphatidylserine and sodium chloride, adding water to full amount, mixing uniformly, and subpackaging into pre-filled syringes to obtain the final product. Can be frozen in a refrigerator at the temperature of minus 80 ℃ for clinical application.
Example 2 compositions of placental MSCs
Ingredient ratio (concentration) of the final product: mesenchymal stem cell, 2X 107Per mL; phosphatidylserine, 0.3%; 0.8 percent of sodium chloride; water for injection and the rest.
The preparation method comprises the following steps: mesenchymal stem cells were obtained from placenta by the method described in examples 1 to 2 in reference to CN102586184A (2012100446386). Weighing phosphatidylserine and sodium chloride, adding a proper amount of water for injection to dissolve, carrying out autoclaving at 121 ℃ for 15 minutes, and cooling for later use; mixing the mesenchymal stem cell suspension with the aqueous solution of phosphatidylserine and sodium chloride, adding water to full amount, mixing uniformly, and subpackaging into pre-filled syringes to obtain the final product. Can be frozen in a refrigerator at the temperature of minus 80 ℃ for clinical application.
Example 3 placental MSC compositions
Ingredient ratio (concentration) of the final product: mesenchymal stem cells, 5 × 107Per mL; phosphatidylserine, 0.1%; 1.0% of sodium chloride; water for injection and the rest.
The preparation method comprises the following steps: mesenchymal stem cells were obtained from placenta by the method described in examples 1 to 2 in reference to CN102586184A (2012100446386). Weighing phosphatidylserine and sodium chloride, adding a proper amount of water for injection to dissolve, carrying out autoclaving at 121 ℃ for 15 minutes, and cooling for later use; mixing the mesenchymal stem cell suspension with the aqueous solution of phosphatidylserine and sodium chloride, adding water to full amount, mixing uniformly, and subpackaging into pre-filled syringes to obtain the final product. Can be frozen in a refrigerator at the temperature of minus 80 ℃ for clinical application.
Example 4 placental MSC compositions
Ingredient ratio (concentration) of the final product: mesenchymal stem cells (third generation), 3 × 107Per mL; phosphatidylserine, 0.2%; 0.9 percent of sodium chloride; water for injection and the rest.
The preparation method comprises the following steps: mesenchymal stem cells were obtained from placenta by the method described in examples 1 to 2 in reference to CN102586184A (2012100446386). Weighing phosphatidylserine and sodium chloride, adding a proper amount of water for injection to dissolve, carrying out autoclaving at 121 ℃ for 15 minutes, and cooling for later use; mixing the mesenchymal stem cell suspension with the aqueous solution of phosphatidylserine and sodium chloride, adding water to full amount, mixing uniformly, and subpackaging into pre-filled syringes to obtain the final product. Can be frozen in a refrigerator at the temperature of minus 80 ℃ for clinical application.
Example 5 composition of umbilical cord MSCs
Ingredient ratio (concentration) of the final product: mesenchymal stem cells (seventh generation), 4X 107Per mL; phosphatidylserine, 0.2%; 0.9 percent of sodium chloride; water for injection and the rest.
The preparation method comprises the following steps: mesenchymal stem cells were obtained from umbilical cord by the method described in example 1 with reference to CN102660497A (2012101599162). Weighing phosphatidylserine and sodium chloride, adding a proper amount of water for injection to dissolve, carrying out autoclaving at 121 ℃ for 15 minutes, and cooling for later use; mixing the mesenchymal stem cell suspension with the aqueous solution of phosphatidylserine and sodium chloride, adding water to full amount, mixing uniformly, and subpackaging into pre-filled syringes to obtain the final product. Can be frozen in a refrigerator at the temperature of minus 80 ℃ for clinical application.
Example 6 composition of umbilical cord MSCs
Ingredient ratio (concentration) of the final product: mesenchymal stem cells (tenth generation), 2X 107Per mL; phosphatidylserine, 0.3%; 0.8 percent of sodium chloride; water for injection and the rest.
The preparation method comprises the following steps: mesenchymal stem cells were obtained from umbilical cord by the method described in example 1 with reference to CN102660497A (2012101599162). Weighing phosphatidylserine and sodium chloride, adding a proper amount of water for injection to dissolve, carrying out autoclaving at 121 ℃ for 15 minutes, and cooling for later use; mixing the mesenchymal stem cell suspension with the aqueous solution of phosphatidylserine and sodium chloride, adding water to full amount, mixing uniformly, and subpackaging into pre-filled syringes to obtain the final product. Can be frozen in a refrigerator at the temperature of minus 80 ℃ for clinical application.
Example 7 composition of umbilical cord MSC
Ingredient ratio (concentration) of the final product: mesenchymal stem cells (primary), 5 × 107Per mL; phosphatidylserine, 0.1%; 1.0% of sodium chloride; water for injection and the rest.
The preparation method comprises the following steps: mesenchymal stem cells were obtained from umbilical cord by the method described in example 1 with reference to CN102660497A (2012101599162). Weighing phosphatidylserine and sodium chloride, adding a proper amount of water for injection to dissolve, carrying out autoclaving at 121 ℃ for 15 minutes, and cooling for later use; mixing the mesenchymal stem cell suspension with the aqueous solution of phosphatidylserine and sodium chloride, adding water to full amount, mixing uniformly, and subpackaging into pre-filled syringes to obtain the final product. Can be frozen in a refrigerator at the temperature of minus 80 ℃ for clinical application.
Example 8 composition of umbilical cord MSCs
Ingredient ratio (concentration) of the final product: mesenchymal stem cells, 3X 107Per mL; phosphatidylserine, 0.2%; 0.9 percent of sodium chloride; water for injection and the rest.
The preparation method comprises the following steps: mesenchymal stem cells were obtained from umbilical cord by the method described in example 1 with reference to CN102660497A (2012101599162). Weighing phosphatidylserine and sodium chloride, adding a proper amount of water for injection to dissolve, carrying out autoclaving at 121 ℃ for 15 minutes, and cooling for later use; mixing the mesenchymal stem cell suspension with the aqueous solution of phosphatidylserine and sodium chloride, adding water to full amount, mixing uniformly, and subpackaging into pre-filled syringes to obtain the final product. Can be frozen in a refrigerator at the temperature of minus 80 ℃ for clinical application.
Example 11 placental MSC compositions
Ingredient ratio (concentration) of the final product: mesenchymal stem cell, 4 × 107Per mL; phosphatidylserine, 0.2%; 0.9 percent of sodium chloride; 0.08 percent of magnesium chloride; calcium sodium ethylene diamine tetraacetate, 0.03%; water for injection and the rest.
The preparation method comprises the following steps: mesenchymal stem cells were obtained from placenta by the method described in examples 1 to 2 of CN102586184A (2012100446386). Weighing phosphatidylserine, sodium chloride, magnesium chloride and ethylene diamine tetraacetic acid calcium sodium, adding a proper amount of water for injection to dissolve, sterilizing for 15 minutes at 121 ℃ under high pressure, and cooling for later use; mixing the mesenchymal stem cell suspension with aqueous solution of phosphatidylserine, sodium chloride, magnesium chloride and ethylene diamine tetraacetic acid calcium sodium, adding water to full amount, mixing uniformly, and subpackaging into pre-filled syringes to obtain the final product. Can be frozen in a refrigerator at the temperature of minus 80 ℃ for clinical application.
Example 12 compositions of placental MSCs
Ingredient ratio (concentration) of the final product: mesenchymal stem cells, 2107Per mL; phosphatidylserine, 0.3%; 0.8 percent of sodium chloride; 0.1 percent of magnesium chloride; calcium sodium ethylene diamine tetraacetate, 0.02%; water for injection and the rest.
The preparation method comprises the following steps: mesenchymal stem cells were obtained from placenta by the method described in examples 1 to 2 of CN102586184A (2012100446386). Weighing phosphatidylserine, sodium chloride, magnesium chloride and ethylene diamine tetraacetic acid calcium sodium, adding a proper amount of water for injection to dissolve, sterilizing for 15 minutes at 121 ℃ under high pressure, and cooling for later use; mixing the mesenchymal stem cell suspension with aqueous solution of phosphatidylserine, sodium chloride, magnesium chloride and ethylene diamine tetraacetic acid calcium sodium, adding water to full amount, mixing uniformly, and subpackaging into pre-filled syringes to obtain the final product. Can be frozen in a refrigerator at the temperature of minus 80 ℃ for clinical application.
Example 13 placental MSC compositions
Ingredient ratio (concentration) of the final product: mesenchymal stem cells, 5 × 107Per mL; phosphatidylserine, 0.1%; 1.0% of sodium chloride; 0.05 percent of magnesium chloride; calcium sodium ethylene diamine tetraacetate, 0.05%; water for injection and the rest.
The preparation method comprises the following steps: mesenchymal stem cells were obtained from placenta by the method described in examples 1 to 2 of CN102586184A (2012100446386). Weighing phosphatidylserine, sodium chloride, magnesium chloride and ethylene diamine tetraacetic acid calcium sodium, adding a proper amount of water for injection to dissolve, sterilizing for 15 minutes at 121 ℃ under high pressure, and cooling for later use; mixing the mesenchymal stem cell suspension with aqueous solution of phosphatidylserine, sodium chloride, magnesium chloride and ethylene diamine tetraacetic acid calcium sodium, adding water to full amount, mixing uniformly, and subpackaging into pre-filled syringes to obtain the final product. Can be frozen in a refrigerator at the temperature of minus 80 ℃ for clinical application.
Example 14 compositions of placental MSCs
Ingredient ratio (concentration) of the final product: mesenchymal stem cells (third generation), 3 × 107Per mL; phosphatidylserine, 0.2%; 0.9 percent of sodium chloride; 0.08 percent of magnesium chloride; calcium sodium ethylene diamine tetraacetate, 0.04%; water for injection and the rest.
The preparation method comprises the following steps: mesenchymal stem cells were obtained from placenta by the method described in examples 1 to 2 of CN102586184A (2012100446386). Weighing phosphatidylserine, sodium chloride, magnesium chloride and ethylene diamine tetraacetic acid calcium sodium, adding a proper amount of water for injection to dissolve, sterilizing for 15 minutes at 121 ℃ under high pressure, and cooling for later use; mixing the mesenchymal stem cell suspension with aqueous solution of phosphatidylserine, sodium chloride, magnesium chloride and ethylene diamine tetraacetic acid calcium sodium, adding water to full amount, mixing uniformly, and subpackaging into pre-filled syringes to obtain the final product. Can be frozen in a refrigerator at the temperature of minus 80 ℃ for clinical application.
Example 15 composition of umbilical cord MSCs
Ingredient ratio (concentration) of the final product: mesenchymal stem cells (seventh generation), 4X 107Per mL; phosphatidylserine, 0.2%; 0.9 percent of sodium chloride; 0.08 percent of magnesium chloride; calcium sodium ethylene diamine tetraacetate, 0.03%; water for injection and the rest.
The preparation method comprises the following steps: mesenchymal stem cells were obtained from umbilical cord by the method described in example 1 with reference to CN102660497A (2012101599162). Weighing phosphatidylserine, sodium chloride, magnesium chloride and ethylene diamine tetraacetic acid calcium sodium, adding a proper amount of water for injection to dissolve, sterilizing for 15 minutes at 121 ℃ under high pressure, and cooling for later use; mixing the mesenchymal stem cell suspension with aqueous solution of phosphatidylserine, sodium chloride, magnesium chloride and ethylene diamine tetraacetic acid calcium sodium, adding water to full amount, mixing uniformly, and subpackaging into pre-filled syringes to obtain the final product. Can be frozen in a refrigerator at the temperature of minus 80 ℃ for clinical application.
Example 16 composition of umbilical cord MSCs
Ingredient ratio (concentration) of the final product: mesenchymal stem cells (tenth generation), 2X 107Per mL; phosphatidylserine, 0.3%; 0.8 percent of sodium chloride; 0.1 percent of magnesium chloride; calcium sodium ethylene diamine tetraacetate, 0.02%; water for injection and the rest.
The preparation method comprises the following steps: mesenchymal stem cells were obtained from umbilical cord by the method described in example 1 with reference to CN102660497A (2012101599162). Weighing phosphatidylserine, sodium chloride, magnesium chloride and ethylene diamine tetraacetic acid calcium sodium, adding a proper amount of water for injection to dissolve, sterilizing for 15 minutes at 121 ℃ under high pressure, and cooling for later use; mixing the mesenchymal stem cell suspension with aqueous solution of phosphatidylserine, sodium chloride, magnesium chloride and ethylene diamine tetraacetic acid calcium sodium, adding water to full amount, mixing uniformly, and subpackaging into pre-filled syringes to obtain the final product. Can be frozen in a refrigerator at the temperature of minus 80 ℃ for clinical application.
Example 17 composition of umbilical cord MSCs
Ingredient ratio (concentration) of the final product: mesenchymal stem cells (primary), 5 × 107Per mL; phosphatidylserine, 0.1%; 1.0% of sodium chloride; 0.05 percent of magnesium chloride; calcium sodium ethylene diamine tetraacetate, 0.05%; water for injection and the rest.
The preparation method comprises the following steps: mesenchymal stem cells were obtained from umbilical cord by the method described in example 1 with reference to CN102660497A (2012101599162). Weighing phosphatidylserine, sodium chloride, magnesium chloride and ethylene diamine tetraacetic acid calcium sodium, adding a proper amount of water for injection to dissolve, sterilizing for 15 minutes at 121 ℃ under high pressure, and cooling for later use; mixing the mesenchymal stem cell suspension with aqueous solution of phosphatidylserine, sodium chloride, magnesium chloride and ethylene diamine tetraacetic acid calcium sodium, adding water to full amount, mixing uniformly, and subpackaging into pre-filled syringes to obtain the final product. Can be frozen in a refrigerator at the temperature of minus 80 ℃ for clinical application.
Example 18 composition of umbilical cord MSCs
Ingredient ratio (concentration) of the final product: mesenchymal stem cells, 3X 107Per mL; phosphatidylserine, 0.2%; 0.9 percent of sodium chloride; 0.08 percent of magnesium chloride; calcium sodium ethylene diamine tetraacetate, 0.04%; water for injection and the rest.
The preparation method comprises the following steps: mesenchymal stem cells were obtained from umbilical cord by the method described in example 1 with reference to CN102660497A (2012101599162). Weighing phosphatidylserine, sodium chloride, magnesium chloride and ethylene diamine tetraacetic acid calcium sodium, adding a proper amount of water for injection to dissolve, sterilizing for 15 minutes at 121 ℃ under high pressure, and cooling for later use; mixing the mesenchymal stem cell suspension with aqueous solution of phosphatidylserine, sodium chloride, magnesium chloride and ethylene diamine tetraacetic acid calcium sodium, adding water to full amount, mixing uniformly, and subpackaging into pre-filled syringes to obtain the final product. Can be frozen in a refrigerator at the temperature of minus 80 ℃ for clinical application.
Example 20: determination of cell viability
For all the cell therapeutic compositions prepared in examples 1 to 8 and examples 11 to 18 of the present invention, viable cells were counted by a known trypan blue exclusion method, and the cell viability (i.e., the proportion of viable cells) was measured and calculated by the following formula:
cell viability ═ 100% (total number of cells-dead cells)/total number of cells
As a result:
the total compositions of examples 1-8 and examples 11-18 above, which were tested to have a cell viability rate in the range of 96-99% prior to cryopreservation (e.g., 98.1% and 96.6% for the compositions of examples 1 and 11, respectively); cell viability ranged from 91-94%% after 6 hours at room temperature prior to cryopreservation (e.g., 93.3% and 91.7% for the example 1 and example 5 compositions, respectively, and 92.3% and 93.6% for the example 11 and example 15 compositions, respectively); the cell viability rate was in the range of 80-84% when the cells were left at room temperature for 24 hours before cryopreservation (e.g., 81.2% and 83.4% for the compositions of examples 1 and 5, and 83.7% and 82.4% for the compositions of examples 11 and 15, respectively), indicating that the cells had excellent viability.
The total compositions of examples 1-8 above, which had cell viability within the range of 85-88% after thawing at room temperature after being frozen in a freezer at-80 ℃ for 10 days (e.g., 85.3% and 86.8% for the compositions of examples 1 and 5, respectively); after recovery, the cell survival rate is in the range of 74-77% after the normal temperature standing for 6 hours (for example, 74.7% and 75.4% of the compositions in example 1 and example 5 respectively), and the cell survival rate is excellent.
The total compositions of examples 11-18 above, which had cell viability within the range of 93-96% after thawing at room temperature after being frozen in a freezer at-80 ℃ for 10 days (e.g., 94.8% and 93.3% for the compositions of examples 11 and 15, respectively); after recovery, the cell viability rate after being left at room temperature for 6 hours is within the range of 89-92% (for example, 91.6% and 90.2% for the compositions of examples 11 and 15, respectively), which indicates that the cells have a better viability rate than those of examples 1-8.
The above-mentioned frozen storage at-80 deg.C for 10 days is short for medicine, and is difficult to meet the conventional requirements for medicine storage and transportation. For example, cells can be cryopreserved at-196 ℃ for a considerable period of time in a classical cryopreservation solution, but when the cells are prepared into a liquid composition for injection, the environment of the cells is changed greatly, long-term cryopreservation is not preferable, and cryopreservation at-80 ℃ for 3 months after filling a prefilled syringe by a pre-preparation method can generally meet the requirements of clinical storage and transportation. Therefore, with reference to the measurement methods herein, all of the compositions of examples 1 to 8 and examples 11 to 18 were frozen at-80 ℃ for 3 months, and then the cell viability of these compositions after thawing at room temperature and after leaving at room temperature for 6 hours after thawing were measured, and as a result:
the total compositions of examples 1-8 above, which had cell viability rates in the range of 61-65% after thawing at room temperature after 3 months in a freezer at-80 ℃ (e.g., 64.3% and 62.7% for the compositions of examples 1 and 5, respectively), and 6 hour cell viability rates in the range of 45-49% as determined (e.g., 45.8% and 47.6% for the compositions of examples 1 and 5, respectively);
the above-mentioned total compositions of examples 11 to 18, which were frozen in a refrigerator at-80 ℃ for 3 months and had cell viability rates after thawing at room temperature within the range of 88 to 91% (e.g., 90.2% and 89.6% for the compositions of examples 11 and 15, respectively), and 6-hour cell viability rates were determined within the range of 83 to 86% (e.g., 84.4% and 85.6% for the compositions of examples 11 and 15, respectively), showed that the cells had more excellent viability rates than those of examples 1 to 8.
Example 21: referring to the formulations and methods of examples 11-18, respectively, except that magnesium chloride was not added, 8 liquid compositions were obtained. Example 22: with reference to the formulation and preparation method of examples 11-18, respectively, except that no calcium sodium ethylenediaminetetraacetate was added, 8 liquid compositions were obtained.
The total compositions of examples 21-22 were frozen in a freezer at-80 ℃ for 3 months, and then thawed at room temperature to recover the cells at a viability rate of 65-69% (e.g., 66.7% and 68.4% for the compositions obtained in example 21 with reference to example 11 and example 15, respectively), and then allowed to stand at room temperature for 6 hours to recover the cells at a viability rate of 46-51% (e.g., 49.7% and 47.3% for the compositions obtained in example 21 with reference to example 11 and example 15, respectively). This result indicates that the unexpected findings of the present invention are: the composition does not contain magnesium chloride or EDTA calcium sodium, and can not obtain excellent cell survival rate after recovery (reflecting the activity of cells undergoing a recovery process) and cell survival rate after 6 hours after recovery (reflecting the survival stability of cells after recovery).
The total cell composition of examples 1-8 and examples 11-18 above, were tested for cell surface markers by flow cytometry, and The following requirements were met in marker assays according to The guidelines published in 2006 for assaying mesenchymal stem cells in The United states "The International Society for Cellular Therapy (ISCT)": positive for expression of markers CD73, CD90, CD 105; markers CD11b, CD34, CD45, CD19, HLA-DR expression negative. The results of the detection of each marker were determined to meet the standard requirements for all of the cell compositions of examples 1-8 and examples 11-18 above.
Example 31: referring to the formulation and preparation of example 11, except that phosphatidylserine was not added, a liquid composition was obtained.
Example 32: referring to the formulation and preparation of example 15, except that phosphatidylserine was not added, a liquid composition was obtained.
Example 33: experimental study on treatment of diabetic rat lower limb ischemia by umbilical cord blood stem cell transplantation
Materials and reagents: the male SD rat is purchased from the center of experimental animals of Suzhou university, is about 10 weeks old and has the weight of 190-230 g; lymphocyte separation liquid is purchased from Mediatech company, low-sugar DMEM culture liquid is purchased from GIBCO company, phosphate buffer solution (PBS, ph6.8) is self-prepared according to 8004 general rules of four parts of chinese pharmacopoeia 2015 edition, rabbit anti-rat viii factor-related antigen is purchased from Sigma company, Streptozotocin (STZ) is purchased from Sigma company, SP9001 immunohistochemical kit is purchased from china fir bridge company, enzyme linked immunosorbent assay (ELISA) detection kit and DAB chromogenic kit for determining Vascular Endothelial Growth Factor (VEGF) are purchased from bosch de organisms; reagent testing: the liquid compositions obtained in example 11, example 15, example 31 and example 32 were stored at 2 to 6 ℃ after preparation and used by injection within 8 hours.
Preparation of diabetic rat lower limb ischemia model: after fasting for 12 hours, 60mg/kg streptozotocin (4mg/mL, 0.1mol/L, pH4.0 sterile citric acid/sodium citrate buffer solution is newly dispensed) is administered to 50 rats left out of 60 male SD rats, one-time intraperitoneal injection is performed according to the weight, after 1 week, the water is continuously cut off for 12 hours, the blood sugar is measured by cutting the tail, the blood sugar concentration is continuously measured to be more than 16.7mmol/L, namely the diabetic rats are considered to be successfully molded [ Thierry Coflinhal, Marcy Silver, Lu P, et Respectively tying 4 parts of external iliac artery and vein and femoral artery and vein muscular branch with 3/0, cutting, suturing tissue skin layer by layer, injecting penicillin 10 uU/mouse for 4 days to prevent infection, preparing diabetic rat lower limb ischemia model, injecting STZ into rat, gradually increasing blood sugar 1 week after injection, all at above 16.7mmol/L, and stably kept at a higher level, the rats gradually appear dark and withered and yellow hair, are disordered and easy to irritate, have thinned skin, have obvious polydipsia and polyuria symptoms, successfully establish a diabetic rat model, successfully model the diabetic male rat, ligate the left lower limb by the blood vessel for 2-3 days, the rats have reduced appetite, gradually atrophy of ischemic left lower limb, reduced lower limb motility, and no obvious gangrene in local part when all the diabetic ischemic lower limb rats successfully molded are killed after 28 days and the materials are taken.
Cell transplantation: the 50 diabetic rat lower limb ischemia model animals were randomly divided into 5 groups, i.e., 10 groups of physiological saline, example 11, example 15, example 31 and example 32, and the following day after the lower limb ischemia model was made, 5 points were selected along the femoral artery direction at intervals of about 0.3cm × 0.3cm, and the graft fluid was injected intramuscularly, and an appropriate amount of the cell therapeutic composition (10) was injected to each point (10 groups of the lower limb ischemia model animals)5The number of the individual cells is one,saline group injected with equal volume of saline in parallel).
Detection of VEGF content in left lower limb muscle tissue: injecting cell therapeutic agent for 4 weeks, dislocating cervical vertebra of rats, cutting left and lower limb muscle tissues of each group of rats, rinsing in ice saline, removing blood stain, soaking dry water with dry gauze, weighing on an electronic balance, weighing 100mg, cutting the specimen into pieces, adding 1ml of PBS solution, placing the container on ice, grinding the muscle tissues into homogenate by a homogenizer, centrifuging at 12000r/min at 4 ℃ for 10min, taking supernatant, and storing at-80 ℃ for later use; detecting the content of VEGF by using an ELISA kit according to the operation of an instruction; the results of the VEGF content (mean ± standard deviation, pg/ml) in the saline solution group, example 11 group, example 15 group, example 31 group and example 32 group were respectively as follows: 138.53 + -26.38, 327.38 + -39.31, 305.67 + -33.48, 247.24 + -36.72, 226.43 + -42.17 (p <0.005, p <0.01 in comparison with the saline group; p <0.05 in comparison with the example 11 group). The invention uses average number + -standard deviation to express result, and uses t test to compare two groups, and uses p <0.05 to judge the difference has statistical significance.
Measurement of capillary density in left lower limb muscle tissue: taking muscles of a rat injection cell therapeutic agent part, embedding paraffin, slicing, wherein the thickness is 4 mu m, performing antigen retrieval, then incubating for 10min by catalase with the volume fraction of 3%, flushing by PBS (phosphate buffer solution), dropwise adding goat serum working solution, incubating for 10min at room temperature, then adding rabbit anti-rat VIII factor related antigen, incubating for 2h at 37 ℃, standing overnight at 4 ℃, then sequentially adding biotin-labeled goat anti-rabbit antibody and horseradish peroxidase-labeled streptavidin working solution, performing DAB (digital audio broadcasting) color development, then fully flushing by tap water, and performing hematoxylin counterstaining; observing the brownish yellow cells under a light mirror, randomly observing 5 visual fields of each sample under a high power mirror (400 times), and calculating the density of capillary vessels; analyzing all data by adopting a statistical software package SPSS 11.0; the results of the capillary density (mean ± sd, counts/HP) of the saline solution group, example 11 group, example 15 group, example 31 group, and example 32 group were respectively: 3.43 ± 0.63, 9.44 ± 0.75 #, 9.73 ± 0.58 #, 7.13 ± 0.54 #, 6.68 ± 0.66 # (p <0.005, p <0.01 as compared to saline group; p <0.05 as compared to example 11 group).
In the experimental period, acute rejection symptoms such as skin bleeding spots and peeling dermatitis are not found in all groups of diabetic lower limb ischemic rats, and the rats are sacrificed after four weeks, and no tumor-like growth is found in the heart, the kidney, the liver, the spleen and the lung.
The above results indicate that the cell therapeutic agents of examples 11 and 15 are significantly superior to the cell therapeutic agents of examples 31 and 32 in terms of their use for treating or preventing ischemic diseases of the lower limbs.
The above-mentioned embodiments are merely preferred embodiments for fully illustrating the present invention, and the scope of the present invention is not limited thereto. The equivalent substitution or change made by the technical personnel in the technical field on the basis of the invention is all within the protection scope of the invention. The protection scope of the invention is subject to the claims.
Claims (10)
1. A cell therapy composition for treating ischemic disease of lower limbs, the composition comprising: umbilical cord mesenchymal stem cells, phosphatidylserine, sodium chloride, and water.
2. The cytotherapeutic composition according to claim 1, characterized in that:
the mass volume percentage of the phosphatidylserine is 0.1-0.3%;
the mass volume percentage of the phosphatidylserine is 0.15-0.25%;
the mass volume percentage of the phosphatidylserine is 0.2%;
the density of the mesenchymal stem cells is 2 x107one/mL to 5X 107Per mL;
the density of the mesenchymal stem cells is 3 x107Per mL;
the mass volume percentage of the sodium chloride is 0.8-1.0%; and/or
The mass volume percentage of the sodium chloride is 0.9%.
3. The cytotherapeutic composition according to claim 1, characterized in that:
wherein the composition further comprises magnesium chloride;
the mass volume percentage of the magnesium chloride is 0.05-0.1%;
the mass volume percentage of the magnesium chloride is 0.08%;
wherein the composition also comprises calcium sodium ethylene diamine tetraacetate;
the mass volume percentage of the ethylene diamine tetraacetic acid calcium sodium is 0.02-0.05%; and/or
The mass volume percentage of the ethylenediaminetetraacetic acid calcium sodium salt is 0.03%.
4. The cytotherapeutic composition according to claim 1, characterized in that:
wherein the mass volume percentage of the phosphatidylserine is 0.1 percent, and the density of the mesenchymal stem cells is 3 multiplied by 107The mass volume percentage of sodium chloride is 0.9 percent per mL;
wherein the mass volume percentage of the phosphatidylserine is 0.2 percent, and the density of the mesenchymal stem cells is 5 multiplied by 107The mass volume percentage of sodium chloride is 0.9 percent per mL; and/or
Wherein the mass volume percentage of the phosphatidylserine is 0.3 percent, and the density of the mesenchymal stem cells is 5 multiplied by 107The mass volume percentage of sodium chloride per mL is 0.9%.
5. The cytotherapeutic composition according to claim 1, characterized in that:
(1) which comprises the following steps: placenta mesenchymal stem cell 4X 107one/mL, phosphatidylserine 0.2%, sodium chloride 0.9%, magnesium chloride 0.08%, calcium sodium ethylene diamine tetraacetate 0.03% and water for injection; or,
(2) which comprises the following steps: placenta mesenchymal stem cell 2X 107one/mL, phosphatidylserine 0.3%, sodium chloride 0.8%, magnesium chloride 0.1%, calcium sodium ethylene diamine tetraacetate 0.02% and water for injection; or,
(3) which comprises the following steps: placenta mesenchymal stem cell 5 × 107one/mL, phosphatidylserine 0.1Percent, 1.0 percent of sodium chloride, 0.05 percent of magnesium chloride, 0.05 percent of sodium calcium ethylene diamine tetraacetate and water for injection; or,
(4) which comprises the following steps: placenta mesenchymal stem cell 3X 107one/mL, phosphatidylserine 0.2%, sodium chloride 0.9%, magnesium chloride 0.08%, calcium sodium ethylene diamine tetraacetate 0.04% and water for injection.
6. The cytotherapeutic composition according to claim 1, characterized in that:
the mesenchymal stem cells are primary mesenchymal stem cells to tenth generation mesenchymal stem cells;
the method for acquiring the mesenchymal stem cells comprises the following steps:
(a) washing the placental lobules sufficiently with PBS buffer to remove residual blood from the placenta;
(b) cutting placenta lobule into pieces, adding PBS buffer solution containing tissue digestive enzyme, and incubating and digesting at 37 deg.C;
(c) filtering the tissue mass with a copper mesh, grinding if necessary to facilitate filtration;
(d) centrifuging the collected filtrate, separating mononuclear cells, suspending the obtained cells in MSC medium, and then adding 5% CO at 37 deg.C2Culturing in an incubator;
(e) after the cells are scattered to form clones, selecting each clone cell, respectively culturing by using an MSC culture medium, and after the cells are fused, digesting and passaging by using pancreatin to obtain the placenta mesenchymal stem cell.
7. The cytotherapeutic composition according to claim 1, which is prepared according to a method comprising the steps of:
dissolving phosphatidylserine and sodium chloride (and optionally magnesium chloride and/or optionally calcium sodium ethylenediaminetetraacetate) in water, optionally sterilizing the solution to obtain matrix of the preparation;
suspending the prepared mesenchymal stem cells in the matrix, and packaging.
8. The cytotherapeutic composition according to claim 7, characterized in that:
the matrix of the formulation is sterilized by means selected from the group consisting of: filtering for sterilization, and sterilizing under hot pressure;
the preparation process is carried out under aseptic condition;
during the preparation process, the temperature of the matrix is lower than 25 ℃ before the matrix is mixed with the mesenchymal stem cells;
in the preparation process, the matrix is mixed with the mesenchymal stem cells at the temperature of lower than 25 ℃;
the subpackaging is to subpackage the prepared cell therapy composition into a pre-filled syringe, in particular to a disposable pre-filled syringe;
the material of the syringe of the prefilled syringe is high molecular polymer (such as polypropylene), and the material of the piston is rubber.
9. A method of preparing a cell therapy composition according to any one of claims 1 to 8, comprising the steps of:
dissolving phosphatidylserine and sodium chloride (and optionally magnesium chloride and/or optionally calcium sodium ethylenediaminetetraacetate) in water, optionally sterilizing the solution to obtain matrix of the preparation;
suspending the prepared mesenchymal stem cells in the matrix, and subpackaging to obtain the composition;
further, in the above-mentioned case,
the preparation process is carried out under aseptic conditions;
during the preparation process, the temperature of the matrix is lower than 25 ℃ before the matrix is mixed with the mesenchymal stem cells;
in the preparation process, the matrix is mixed with the mesenchymal stem cells under the condition that the temperature is lower than 25 ℃.
10. Use of a cell therapy composition according to any one of claims 1 to 8 in the manufacture of a medicament for the treatment and/or prevention of ischemic diseases of the lower extremities.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911352949.7A CN110974847B (en) | 2019-12-25 | 2019-12-25 | Method for treating lower limb ischemic diseases by using stem cells |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911352949.7A CN110974847B (en) | 2019-12-25 | 2019-12-25 | Method for treating lower limb ischemic diseases by using stem cells |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110974847A true CN110974847A (en) | 2020-04-10 |
CN110974847B CN110974847B (en) | 2021-07-06 |
Family
ID=70075179
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911352949.7A Active CN110974847B (en) | 2019-12-25 | 2019-12-25 | Method for treating lower limb ischemic diseases by using stem cells |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110974847B (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110840914A (en) * | 2019-11-23 | 2020-02-28 | 博雅干细胞科技有限公司 | Method for alleviating or improving vascular disorders using cell therapeutic agent |
CN110882276A (en) * | 2019-11-23 | 2020-03-17 | 博雅干细胞科技有限公司 | Cell therapy compositions and methods for treating vascular disorders |
CN111012801A (en) * | 2019-12-25 | 2020-04-17 | 博雅干细胞科技有限公司 | Stem cell therapeutic agent for treating ischemic diseases of lower limbs and use thereof |
CN115350322A (en) * | 2022-09-14 | 2022-11-18 | 山东大学 | Preparation method of calcium nervonate nanoparticles and application of calcium nervonate nanoparticles in preparation of bone defect repair material |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004307772A (en) * | 2003-04-03 | 2004-11-04 | Yamaguchi Michiko | Eutectic crystal composition for latent cold heat storage |
CN101631475A (en) * | 2007-01-18 | 2010-01-20 | 福瑞托-雷北美有限公司 | Method for reducing acrylamide formation |
CN101856016A (en) * | 2010-06-19 | 2010-10-13 | 张尤嘉 | Diluent for preserving porcine semen at normal temperature |
CN102586184A (en) * | 2011-09-05 | 2012-07-18 | 博雅干细胞科技有限公司 | Method for establishing placental mesenchyme stem cell library |
CN105463058A (en) * | 2016-01-06 | 2016-04-06 | 北京汉氏联合生物技术股份有限公司 | Quantitative method for detecting angiogenesis promotion ability of MSC |
CN105796600A (en) * | 2016-04-28 | 2016-07-27 | 博雅干细胞科技有限公司 | Method for treating osteoarthritis by stem cells and composition |
CN106754680A (en) * | 2015-12-31 | 2017-05-31 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | A kind of separation method of placenta derived stem cells and its application |
CN109674819A (en) * | 2018-12-21 | 2019-04-26 | 博雅干细胞科技有限公司 | Placenta mesenchyma stem cell preparation and its purposes for treating hardening illness |
-
2019
- 2019-12-25 CN CN201911352949.7A patent/CN110974847B/en active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004307772A (en) * | 2003-04-03 | 2004-11-04 | Yamaguchi Michiko | Eutectic crystal composition for latent cold heat storage |
CN101631475A (en) * | 2007-01-18 | 2010-01-20 | 福瑞托-雷北美有限公司 | Method for reducing acrylamide formation |
CN101856016A (en) * | 2010-06-19 | 2010-10-13 | 张尤嘉 | Diluent for preserving porcine semen at normal temperature |
CN102586184A (en) * | 2011-09-05 | 2012-07-18 | 博雅干细胞科技有限公司 | Method for establishing placental mesenchyme stem cell library |
CN106754680A (en) * | 2015-12-31 | 2017-05-31 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | A kind of separation method of placenta derived stem cells and its application |
CN105463058A (en) * | 2016-01-06 | 2016-04-06 | 北京汉氏联合生物技术股份有限公司 | Quantitative method for detecting angiogenesis promotion ability of MSC |
CN105796600A (en) * | 2016-04-28 | 2016-07-27 | 博雅干细胞科技有限公司 | Method for treating osteoarthritis by stem cells and composition |
CN109674819A (en) * | 2018-12-21 | 2019-04-26 | 博雅干细胞科技有限公司 | Placenta mesenchyma stem cell preparation and its purposes for treating hardening illness |
Non-Patent Citations (4)
Title |
---|
WINEGRAD, S等: "Studies of cardiac muscle with a high permeability to calcium produced by treatment with ethylenediaminetetraacetic acid.", 《THE JOURNAL OF GENERAL PHYSIOLOGY》 * |
周锦帆等: "阳离子交换分离法测定铀矿石硫酸浸出液中游离酸 ", 《铀矿冶》 * |
庞国明等: "《围产期成体干细胞基础与临床应用》", 31 October 2016, 中国中医药出版社 * |
王永芬等: "《动物生物制品技术》", 31 August 2011, 中国农业大学出版社 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110840914A (en) * | 2019-11-23 | 2020-02-28 | 博雅干细胞科技有限公司 | Method for alleviating or improving vascular disorders using cell therapeutic agent |
CN110882276A (en) * | 2019-11-23 | 2020-03-17 | 博雅干细胞科技有限公司 | Cell therapy compositions and methods for treating vascular disorders |
CN110882276B (en) * | 2019-11-23 | 2021-07-06 | 博雅干细胞科技有限公司 | Cell therapy compositions and methods for treating vascular disorders |
CN110840914B (en) * | 2019-11-23 | 2021-07-06 | 博雅干细胞科技有限公司 | Method for alleviating or improving vascular disorders using cell therapeutic agent |
CN111012801A (en) * | 2019-12-25 | 2020-04-17 | 博雅干细胞科技有限公司 | Stem cell therapeutic agent for treating ischemic diseases of lower limbs and use thereof |
CN115350322A (en) * | 2022-09-14 | 2022-11-18 | 山东大学 | Preparation method of calcium nervonate nanoparticles and application of calcium nervonate nanoparticles in preparation of bone defect repair material |
CN115350322B (en) * | 2022-09-14 | 2023-03-07 | 山东大学 | Preparation method of calcium nervonate nanoparticles and application of calcium nervonate nanoparticles in preparation of bone defect repair material |
Also Published As
Publication number | Publication date |
---|---|
CN110974847B (en) | 2021-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110974847B (en) | Method for treating lower limb ischemic diseases by using stem cells | |
US20200377859A1 (en) | Umbilical cord mesenchymal stem cells (mscs) and culture method and application thereof | |
US8142993B1 (en) | Method of preparing neutrophil-depleted platelet-rich plasma | |
JPH07508275A (en) | Thrombin blood fraction used in medical procedures | |
US20230129268A1 (en) | Platelet rich plasma formulations | |
JP2020504167A (en) | Method for preparing a growth factor-containing platelet release | |
JP7416786B2 (en) | Method for preparing platelet release material | |
US20210198626A1 (en) | Compositions and methods for cell culture | |
CN107249603A (en) | Separate hematoblastic method | |
Sánchez et al. | Platelet rich plasma (PRP) biotechnology: concepts and therapeutic applications in orthopedics and sports medicine | |
Monteiro et al. | Biologic strategies for intra-articular treatment and cartilage repair | |
Evans et al. | How fat grafting works | |
US20210154235A1 (en) | Stromal stem cell therapeutics and methods of use | |
AU2023206197A1 (en) | Enhanced multipotent cells and microvascular tissue and methods of use thereof | |
CN106701682A (en) | Method for separating hematopoietic stem cells from umbilical cord blood and amplifying CD34 positive cells | |
RU2455354C1 (en) | Skin and mucosa cell renewal composition | |
CN111012801B (en) | Stem cell therapeutic agent for treating ischemic diseases of lower limbs and use thereof | |
RU2638796C1 (en) | Method for obtaining of two-component preparation for treatment of joints damage by low-invasive introduction into joint bag and preparation obtained by this method | |
Sobajima et al. | Adipose-derived stem cells: Use in clinical medicine | |
KR20200132550A (en) | A composition for preventing or treating of blood vessel disease comprising tonsil-derived mesenchymal stem cell or conditioned medium thereof | |
RU2822010C1 (en) | Method of treating cardiovascular disease | |
CN110840914B (en) | Method for alleviating or improving vascular disorders using cell therapeutic agent | |
Leong et al. | Biologic Injections in the Treatment of Cartilage Defects | |
Ruiz‐Lopez et al. | Complications in Regenerative Medicine | |
US20210137990A1 (en) | Methods for exp anding adipose-derived stem cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |